Dr. Linden is the Director of Hematopathology and Brunning Professor. During his graduate studies, he spearheaded the development of groundbreaking genetically engineered mouse models of multiple myeloma, mimicking many of the features of the human disease. Notably, one of these models yielded long-lived polyclonal plasma cells, a breakthrough technology crucial in producing reagent antibodies for research purposes. Since completing his clinical training, Dr. Linden has focused his myeloma research on advancing laboratory diagnoses, clinical monitoring, and predicting disease resistance to therapy.
